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Abstract
Guest Editors of Thyroid Research supplement devoted to medullary thyroid cancer present the history on how the
discussion about “Medullary Thyroid Cancer: management guidelines of the American Thyroid Association” was initiated
and subsequently widely commented before and during European Thyroid Association – Cancer Research Network
Meeting in Lisbon. It is explained why it has been decided to publish the manuscripts within the supplement – to
document voices from the discussion and popularize them.
The publication of important paper by R. Kloos et al.
“Medullary Thyroid Cancer: management guidelines of the
American Thyroid Association” [1] has been a great
achievement in the world of thyroidology in general and
thyroid cancer in particular. The guidelines were evidence
based for management of medullary thyroid cancer, a very
rare cancer type, known well only to few thyroidologists.
These were crucial factors for their endorsement by the
European Thyroid Association. However, among some
European thyroidologists the document raised a vivid
online discussion, which led to the organization of this
topic as the program of the European Thyroid Association
– Cancer Research Network Meeting (ETA-CRN) in
Lisbon in September 2009. The program of this event is
presented in Additional file 1. About 140 participants,
mostly European thyroidologists, took part in the discus-
sion [2]. This supplement of Thyroid Research is to sum-
marize aroused debate on the subjects in question. The
publication followed the request from ETA-CRN General
Assembly in Pisa, 2012 and the disputants were invited to
present their views. Therefore, Ulla Feldt-Rasmussen,
President of ETA-CRN and Barbara Jarzab, Secretary of
ETA-CRN undertook the role as Guest Editors of this
supplement.
We are very thankful that the authors agreed to join the
supplement on a voluntary basis and undertook the chal-
lenge to formulate conclusions from Lisbon and update
them. We believe that more than a 3-year long delay allowed
to balance and objectify the assessment of the ATA medul-
lary thyroid cancer guidelines well. We have also invited col-
leagues, members of ETA-CRN, who took active part in the
online discussion but did not have the possibility to join
discussion in Lisbon [3,4]. Please note, that all invited
articles have been peer reviewed before publication, accord-
ing to BioMed Central Guidelines for externally adminis-
tered peer-review. We asked all peer reviewers to declare
their competing interests in relation to reviewed paper.
We hope this supplement, devoted to medullary thyroid
cancer, will enrich our knowledge about this rare disease
and its treatment, and will become a positive contribution
in the study of its nature.
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